Welcome to our dedicated page for Nu Skin Enter SEC filings (Ticker: NUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nu Skin Enterprises, Inc. filings document the company’s operating results, governance, executive leadership changes and financing arrangements. Recent 8-K reports include quarterly and annual financial-result releases, officer appointments and resignations, compensation arrangements, and material definitive agreements tied to amended credit facilities.
The company’s proxy materials provide annual meeting governance and executive-compensation disclosures, including board and compensation matters reported under Schedule 14A. Nu Skin’s regulatory record also reflects its capital structure and liquidity arrangements, including term loan and revolving credit facilities, alongside formal disclosures for its beauty and wellness operations, affiliate platform and Rhyz-related business activities.
Nu Skin Enterprises director James M. Winett reported both an equity grant and a sale of Class A Common Stock. On June 1, 2026, he acquired 26,643 shares as a grant at $0.00 per share. On June 2, 2026, he executed an open-market sale of 7,203 shares at $5.62 per share pursuant to a Rule 10b5-1(c) trading plan adopted on November 11, 2025. After these transactions, he directly holds 37,448 shares of Nu Skin’s Class A Common Stock, indicating he retained a substantial position following the sale.
Nathanson Laura reported acquisition or exercise transactions in this Form 4 filing.
NU SKIN ENTERPRISES, INC. director Laura Nathanson received a grant of 26,643 shares of Class A Common Stock on June 1, 2026. The shares were awarded at no purchase price, increasing her directly held stake to 57,116 shares after the transaction. This reflects compensation in equity rather than a market purchase.
Zorko Mark A reported acquisition or exercise transactions in this Form 4 filing.
NU SKIN ENTERPRISES, INC. director Mark A. Zorko received a grant of 26,643 shares of Class A Common Stock on June 1, 2026 at no purchase price. Following this equity award, he directly holds 60,586 shares. This is a compensation-related grant, not an open-market trade.
NU SKIN ENTERPRISES, INC. director Edwina D. Woodbury reported both a sale and a stock grant of Class A Common Stock. On June 1, 2026, she executed an open-market sale of 7,203 shares at $5.70 per share. The same day, she acquired 26,643 shares through a grant or award at no stated purchase price. Following these transactions, her direct holdings totaled 69,636 shares of Class A Common Stock. The footnote states the sale occurred under a pre-arranged trading plan intended to comply with Rule 10b5-1(c) adopted on February 19, 2026, indicating the sale’s timing was planned in advance.
NU SKIN ENTERPRISES, INC. director Emma S. Battle received a grant of Class A Common Stock as equity compensation. She acquired 26,643 shares at a stated price of $0.0000 per share, increasing her direct holdings to 57,648 shares of Class A Common Stock following the transaction.
Thomas Pisano R. reported acquisition or exercise transactions in this Form 4 filing.
NU SKIN ENTERPRISES, INC. director Thomas R. Pisano received a grant of Class A Common Stock as equity compensation. On June 1, 2026, he was awarded 26,643 shares at no purchase price, reflecting a stock-based award rather than an open-market buy. Following this grant, he directly holds 116,827 shares of Nu Skin Class A Common Stock, indicating the transaction increased his equity stake through a routine compensation-related award.
CAMPBELL DANIEL W reported acquisition or exercise transactions in this Form 4 filing.
NU SKIN ENTERPRISES, INC. director Daniel W. Campbell received a grant of 26,643 shares of Class A Common Stock at no cash cost, increasing his direct holdings to 65,859 shares. He also has indirect ownership of 10,010 shares through a limited liability company he and his spouse own and control, and 53,375 shares through an irrevocable family trust.
Nu Skin Enterprises, Inc. reported results from its 2026 Annual Meeting of Stockholders. Stockholders approved and adopted the Amended and Restated 2024 Omnibus Incentive Plan, which had previously been approved by the board and its Compensation and Human Capital Committee, subject to stockholder approval.
All nine director nominees, including Emma S. Battle and Ryan S. Napierski, were elected with over 33.5 million votes each in favor and 5,430,258 broker non-votes recorded for each seat. Stockholders gave advisory approval of the Company’s executive compensation with 33,111,458 votes for, 1,255,101 against, and 37,082 abstentions.
Approval of the Amended and Restated 2024 Omnibus Incentive Plan received 24,185,333 votes for, 10,177,825 against, and 40,483 abstentions. Stockholders also ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm, with 38,798,633 votes for, 970,082 against, and 65,184 abstentions.